Table 1.
Predictor | DSS success | DSS positive effects | DSS negative effects | Objective discontinuation | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|
b | t | R2 | b | t | R2 | b | t | R2 | OR | z | |
Sociodemographic data | |||||||||||
Age | 0.00 | 0.13 | <0.001 | 0.03 | 0.59 | 0.001 | −0.07 | −1.52 | 0.008 | 0.99 | −0.83 |
Gender (female v. male) | −0.46 | −0.63 | 0.002 | −0.74 | −0.51 | 0.001 | −0.42 | −0.32 | <0.001 | 0.43** | −2.84 |
Education (high v. low) | −0.36 | −0.52 | 0.001 | 0.93 | 0.68 | 0.002 | −2.16+ | −1.72 | 0.011 | 1.19 | 0.66 |
Clinical and medication history | |||||||||||
Duration of disorder | −0.01 | −0.41 | 0.001 | −0.02 | −0.36 | 0.001 | 0.00 | 0.08 | <0.001 | 1.02 | −0.90 |
Discontinuation of SSRI | 0.42 | 0.67 | 0.002 | −0.92 | −0.73 | 0.002 | −0.10 | −0.08 | <0.001 | 1.18 | 0.07 |
Discontinuation of SNRI | −1.14+ | −1.80 | 0.012 | −1.01 | −0.78 | 0.002 | 0.33 | 0.28 | <0.001 | 0.79 | −0.92 |
Discontinuation of tri/tetracyclic AD | 2.11* | 2.59 | 0.026 | 2.55 | 1.54 | 0.009 | 1.39 | 0.90 | 0.003 | 3.08** | 3.10 |
Duration of medication intake | 0.03 | 0.65 | 0.002 | 0.07 | 0.86 | 0.003 | −0.01 | −0.12 | <0.001 | 0.98 | −1.17 |
Multiple discontinued drugs (v. one) | 2.37*** | 3.38 | 0.042 | 3.88** | 2.71 | 0.028 | −0.79 | −0.59 | 0.001 | 1.37 | 1.11 |
Concomitant medication | −0.36 | −0.42 | 0.001 | −4.01* | 2.36 | 0.022 | 1.44 | 0.91 | 0.003 | 0.61 | −1.44 |
Professional support | |||||||||||
Shared decision-making | 0.11*** | 3.74 | 0.051 | 0.03 | 0.59 | 0.001 | −0.12* | −2.24 | 0.019 | 0.99 | −0.60 |
Therapeutic alliance | 0.75*** | 4.20 | 0.065 | 0.17 | 0.45 | 0.001 | −0.99** | −2.95 | 0.033 | 0.91 | −1.35 |
Psychotherapy during attempt | 0.22 | 0.35 | <0.001 | −0.70 | −0.55 | 0.001 | −0.67 | −0.58 | 0.001 | 0.97 | −0.14 |
Circumstances | |||||||||||
Unstable situation | 0.02 | 0.53 | 0.001 | 0.014 | 0.66 | 0.002 | 0.04 | 0.66 | 0.002 | 1.03* | 2.15 |
Discontinuation strategy | |||||||||||
Preparation | 0.02 | 0.05 | <0.001 | 0.45 | 0.64 | 0.002 | −1.15+ | −1.79 | 0.012 | 0.77+ | −1.89 |
Followed a tapering plan | −0.06 | −0.21 | <0.001 | −0.31 | −0.55 | 0.001 | −0.27 | −0.52 | 0.001 | 0.67*** | −3.38 |
Adjustment phasesa | 0.48+ | 1.71 | 0.014 | 0.72 | 1.24 | 0.008 | −1.27** | −2.39 | 0.028 | 0.71** | −2.99 |
Flexible reductiona | −0.47 | −1.49 | 0.011 | 0.09 | 0.13 | <0.001 | 0.56 | 0.92 | 0.004 | 1.20 | 1.44 |
Accelerated pacing (v. slow)a | 2.61** | 2.80 | 0.049 | −1.05+ | −0.55 | 0.002 | −0.37 | −0.24 | 0.051 | 2.40* | 2.17 |
Coping strategies | |||||||||||
Physical care | −0.49 | −1.33 | 0.007 | 1.37+ | 1.86 | 0.013 | −0.45 | −0.66 | 0.002 | 0.96 | −0.27 |
Relaxation | −0.08 | 0.17 | <0.001 | 3.08*** | 3.67 | 0.051 | −0.07 | −0.09 | <0.001 | 0.95 | −0.27 |
Mindful awareness | 1.50*** | 4.72 | 0.080 | 3.44*** | 5.41 | 0.102 | −3.76*** | −6.54 | 0.145 | 0.98 | −0.14 |
Self-compassion | 0.84* | 2.52 | 0.024 | 3.40*** | 5.32 | 0.102 | −2.62*** | −4.33 | 0.069 | 1.12 | 0.85 |
Supportive relationships | 0.94** | 2.79 | 0.030 | 2.73*** | 4.14 | 0.064 | −2.98*** | −4.92 | 0.087 | 0.78+ | −1.82 |
Supportive structures | 0.53 | 1.62 | 0.010 | 3.25*** | 4.78 | 0.084 | −2.79*** | −4.39 | 0.071 | 0.71* | −2.40 |
Drug consumption | 0.53 | 1.51 | 0.009 | 0.62 | 0.86 | 0.003 | 0.09 | 0.14 | <0.001 | 1.26 | 1.62 |
Note: Regression analyses with one predictor and one dependent variable.
Only participants who indicated to have followed a tapering plan responded to the questions on the details of the tapering plan (n = 200).
Significance levels: +p < 0.1, *p < 0.05, **p < 0.01, ***p < 0.001. Significant effects are printed in bold.